Material Agreement Form 8 K

Item 1.01Entry into a Material Definitive Agreement.

On September 25, 2024, INVO Bioscience, Inc. (the "Company") entered into a Standard Merchant Cash Advance Agreement (the "Agreement") with a buyer (the "Buyer") under which the Buyer purchased $384,250 of the Company's future sales for a gross purchase price of $265,000 (the "Transaction"). The Company received net proceeds of $251,750. Until the purchase price has been repaid, the Company agreed to pay the Buyer $9,606 per week. The Company intends to use the proceeds for working capital and general corporate purposes.

The Company received approval from its senior secured lender, Decathlon Alpha V, L.P. ("Decathlon") to consummate the Transaction pursuant to an Amended and Restated First Amendment (the "Amendment") to Revenue Loan and Security Agreement, dated September 29, 2023 between the Company and Decathlon (the "Revenue Loan and Security Agreement"). Pursuant to the Amendment, the minimum interest multiples set forth in the Revenue Loan and Security Agreement will automatically increase by 0.15x as of December 1, 2024 if the Company does not receive equity investments in the net amount of $1,000,000 by November 30, 2024.

Decathlon, the Buyer, and the Company also signed a subordination agreement in which the Buyer subordinated its rights under the transaction to those of Decathlon.